Iva Toudjarska

First-in-Humans Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement

Josep Tabernero, Geoffrey I. Shapiro, Patricia LoRusso et al. · Cancer Discovery · 2013 · 699 citations

Pharmacy, Oncology, Pharmaceutics +17

Split-Hand/Split-Foot Malformation Is Caused by Mutations in the p63 Gene on 3q27

Peter Ianakiev, Michael W. Kilpatrick, Iva Toudjarska et al. · The American Journal of Human Genetics · 2000 · 293 citations · Full text

Life Sciences, Genetics, Molecular Genetics +8

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)

John P. DeVincenzo, Jeff Cehelsky, Rene Alvarez et al. · Antiviral Research · 2008 · 246 citations

Medicine, Pharmacokinetics, Pharmacology +14

An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe−/− mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia

Paul J. Schmidt, Iva Toudjarska, Anoop K. Sendamarai et al. · Blood · 2012 · 197 citations · Full text

Medicine, Hematology, Molecular Biology +13

Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.

Andrés Cervantes, María Alsina, Josep Tabernero et al. · Journal of Clinical Oncology · 2011 · 55 citations

Medicine, Oncology, Pharmacology +14